Vor Biopharma Inc.

NASDAQ:VOR

Biotechnology

Healthcare
$17.83 -2.26%

-$0.34 today

Market cap
$966.13M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$2,053.13
52W Low $4.28High $65.80

Volume 0.79M

Average 1.07M

VOR Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Vor Biopharma Inc.NASDAQ: VOR

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns negative

Q1 FY2026 other income / expenses was -$184.43M, compared with $805K a year earlier. Trailing-twelve-month other income / expenses was -$509.57M.

Context

  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -$184.43M or moves back toward the trailing-twelve-month quarterly average of -$127.39M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$184.43M-110.5% QoQ
Last fiscal yearDec 2025
-$324.34M-7694.0% YoY
LTMMar 2026
-$509.57M-14437.9% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23009.9%——
1 year-7694.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(324.34M) USD
Year-over-year change
-7694.0%

Other Income / Expenses vs competitors

How VOR compares with its peers on the latest reported figures

  • VOR's LTM Mar 2026 other income / expenses of -$509.57M is the lowest of the 10 companies compared; the peer median is $9.09M.
  • Its year-over-year change of -14437.9% is the lowest of 10, against a peer median of -32.3%.
VOR Competitors Peer median
Other Income / Expenses for VOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRSPCRISPR Therapeutics AGLTM Sep 2026$76.21M +1284.2%—302.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$26.12M +72.4%—39.5%
NKTXNkarta, Inc.LTM Mar 2026$16.38M -21.0%+49.6%—
FATEFate Therapeutics, Inc.LTM Mar 2026$9.52M -61.3%-24.7%150.7%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$9.09M -27.2%+21.7%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$6.49M -46.8%+29.6%—
EDITEditas Medicine, Inc.LTM Mar 2026$6.16M -32.3%—15.9%
SANASana Biotechnology, Inc.LTM Mar 2026-$4.43M -212.0%——
AUTLAutolus Therapeutics plcLTM Mar 2026-$23.51M -111.8%—25.4%
VORVor Biopharma Inc.LTM Mar 2026-$509.57M -14437.9%——
Peer median (excluding VOR) $9.09M-32.3%+25.6%39.5%

Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue08.96M3.49M00
Gross Profit0(8.96M)(3.49M)00
Gross Margin—————
Research & Development47.53M64.55M94.32M93.31M321.53M
Selling, General & Admin21.49M19.91M31.72M27.88M50.11M
Operating Expenses69.02M84.46M122.54M121.19M371.64M
Depreciation & Amortization1.43M8.96M3.49M3.53M2.89M
EBITDA(67.47M)(83.13M)(114.37M)(113.39M)(693.09M)
EBITDA Margin—————
Operating Income(69.02M)(93.42M)(126.04M)(121.19M)(371.64M)
Operating Margin—————
Interest Income119K1.32M8.17M4.27M5.87M
Interest Expense00000
Other Income / Expenses119K1.32M8.17M4.27M(324.34M)
Income Before Tax(68.9M)(92.09M)(117.86M)(116.91M)(695.98M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(68.9M)(92.09M)(117.86M)(116.91M)(695.98M)
Net Margin—————
EPS (Basic)(37.80)(46.60)(35.00)(34.00)(70.50)
EPS (Diluted)(37.80)(46.60)(35.00)(34.00)(70.50)
Weighted Avg Shares1.86M1.98M3.36M3.44M9.87M
Weighted Avg Shares (Diluted)1.86M1.98M3.36M3.44M9.87M

Vor Biopharma Inc.

NASDAQ:VOR

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.